Department of Pediatrics, Division of Pediatric Pulmonology; Horae Gene Therapy Center
Genetics and Genomics | Therapeutics | Translational Medical Research
Introduction: Gene therapy has changed dramatically in the 28 years since the first human gene transfer experiment in 1989. Alipogene tiparvovec, GlyberaR®, a recombinant adeno-associated virus (rAAV) product for lipoprotein lipase deficiency, and Strimvelis®, a lentivirus vector for severe combined immune deficiency are approved in Europe. An rAAV2 product for a congenital form of blindness is currently under review in the United States, likely to be followed by numerous other gene therapies.
Rights and Permissions
Copyright 2017 The Authors.
DOI of Published Version
Clin Transl Sci. 2017 Apr 6. doi: 10.1111/cts.12466. Link to article on publisher's site
Clinical and translational science
Keeler AM, Elmallah MK, Flotte TR. (2017). Gene Therapy 2017: Progress and Future Directions. Pediatric Publications. https://doi.org/10.1111/cts.12466. Retrieved from https://escholarship.umassmed.edu/peds_pp/125
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License